Hessam Aazami, MD
General Practice · Canoga Park, CANPI 1144299173
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $10,881 of the $14,948 with a category attached, or 72.8%. 29 manufacturers reported payments, led by Amgen at 27.6% of the total. Among general practice clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 426 payments — averaging $35.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$4K
- Eli Lilly$2K
- Modernatx, Inc.$1K
- AbbVie$1K
- Johnson & Johnson$1K
- Novo Nordisk$691
- plus $5K from 23 others
Across 7,583 payments — averaging $11,733 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$59.6M
- Regeneron$7.8M
- Pfizer$6.5M
- Eli Lilly$3.9M
- AbbVie$1.4M
- Novartis$1.1M
- plus $8.6M from 38 others
What the payments were for
- Travel & lodging$4,00127%
- Food & beverage$10,88173%
- Education$660%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 119 | $4,121 |
| Eli Lilly | 24 | $1,670 |
| Modernatx, Inc. | 4 | $1,465 |
| AbbVie(2 entities) | 14 | $1,380 |
| Johnson & Johnson | 30 | $1,061 |
| Novo Nordisk | 27 | $691 |
| Sanofi-aventis U.S. LLC | 27 | $533 |
| AstraZeneca | 23 | $528 |
| Lilly USA, LLC | 26 | $501 |
| Boehringer Ingelheim | 22 | $472 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 15 | $313 |
| Pfizer | 24 | $295 |
| Bayer | 7 | $267 |
| Merck | 14 | $261 |
| Amarin Pharma, Inc. | 11 | $207 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $192 |
| GSK | 6 | $189 |
| Ardelyx, Inc. | 5 | $163 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $131 |
| Exact Sciences | 1 | $122 |
| Biohaven Pharmaceuticals, Inc. | 5 | $107 |
| Astellas Pharma US Inc | 3 | $60 |
| Genentech, Inc. | 1 | $50 |
| Mannkind Corporation | 1 | $38 |
| Corcept Therapeutics | 1 | $38 |
| Abbott | 2 | $35 |
| Novartis | 1 | $24 |
| Nestle Healthcare Nutrition Inc. | 1 | $19 |
| Phadia US Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,948 in reported general payments places this provider in the 95th percentile of 12,963 general practice providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 128 | $123,999 |
| VascepaIcosapent Ethyl | 249 | $102,690 |
| FarxigaDapagliflozin Propanediol | 113 | $85,960 |
| RybelsusSemaglutide | 34 | $68,348 |
| JardianceEmpagliflozin | 73 | $61,406 |
| LinzessLinaclotide | 57 | $40,587 |
| MounjaroTirzepatide | 14 | $24,854 |
| Repatha SureclickEvolocumab | 32 | $24,163 |
| Icosapent Ethyl | 89 | $21,821 |
| JanumetSitagliptin Phos/Metformin Hcl | 19 | $20,949 |
| EliquisApixaban | 29 | $16,020 |
| Diclofenac Sodium | 36 | $13,356 |
| TradjentaLinagliptin | 25 | $13,125 |
| SynjardyEmpagliflozin/Metformin Hcl | 13 | $8,320 |
| BelsomraSuvorexant | 15 | $6,289 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $691 | $192,347162 claims |
| AstraZenecaFarxiga, Brilinta | $528 | $91,723126 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy | $472 | $82,850111 claims |
| AbbVieLinzess | $1,380 | $40,58757 claims |
| MerckJanumet, Belsomra | $261 | $27,23834 claims |
| Lilly USA, LLCMounjaro | $501 | $24,85414 claims |
| PfizerEliquis | $295 | $16,02029 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 12,963 general practice providers in California.
Other general practice in Canoga Park
- Nathan LiLancaster$5.2M
- Milton McCollSan Jose$4.9M
- Frederic MollRedwood City$2.5M
- Bradley ChingUpland$1.4M
- Eric BrassTorrance$755K
- Marc GeissbergerGreenbrae$583K
- Robert CampbellLong Beach$501K
- Varo BoyerNorth Hills$482K
- Michael MiyasakiSacramento$464K
- Apolinar MadrigalCeres$419K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.